April 2015: Product Liability Litigation Update

by Quinn Emanuel Urquhart & Sullivan, LLP

Defenses to Public Nuisance Claims in Pharmaceutical Products Litigation. For many years, plaintiffs have asserted the tort of nuisance to address purported harms from all sorts of products—including firearms, lead paint, chemicals, and energy products—that are alleged to endanger the “health, morals, safety, comfort, convenience, or welfare of the community.” Recently, nuisance has been asserted on behalf of governmental entities to address alleged harms arising from pharmaceutical products. As discussed below, these claims are subject to a variety of defenses.

The new nuisance lawsuits have been brought on behalf of governmental entities alleging wrongdoing in connection with prescription pain medications manufactured or distributed by a number of pharmaceutical defendants. In separate actions, the City of Chicago and two California counties are suing the drug industry for its “aggressive marketing” of opioid pain medications, which they allege has led to an epidemic of addiction that has cost taxpayers millions of dollars in insurance claims and other healthcare costs, criminal use of the medications, and an expanded market for heroin. E.g., Compl. at 94-97, California v. Purdue Pharma LP, No. 30-2014-00725287-CU-BT-CXC (Cal. Super. Ct. May 21, 2014); Compl. at 126-55, City of Chicago v. Purdue Pharma L.P., No. 14-cv-04361 (N.D. Ill.. Oct. 21, 2014).

Federal preemption may be a significant defense to public nuisance suits brought against pharmaceutical manufacturers. Long a staple defense in pharmaceutical products liability litigation, preemption has also been held to bar public nuisance claims in other contexts. For example, the Fourth Circuit held that air pollution claims were barred by the Clean Air Act’s “system for accommodating the need for energy production and the need for clean air,” N. Carolina, ex rel. Cooper v. Tenn. Valley Auth., 615 F.3d 291, 296 (4th Cir. 2010), and the Supreme Court has held that federal common law nuisance claims regarding carbon dioxide emissions alleged to cause global warming were displaced by the Clean Air Act. Am. Elec. Power Co. v. Connecticut, 131 S. Ct. 2527 (2011).

Defendants may assert that preemption similarly bars or substantially limits public nuisance claims against pharmaceutical companies. At the outset, defendants may argue that any claims involving generic medications would be significantly curtailed by the Supreme Court’s decisions in PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), and Mutual Pharmaceutical Co. v. Bartlett, 133 S. Ct. 2466 (2013), because federal law requires generic manufacturers to use both the same labeling and design as the branded medication and limits communications to physicians regarding generic medications. Further, to the extent these actions are based on alleged violations of the Federal Food, Drug, and Cosmetic Act (“FDCA”) requirements, defendants may argue that they would be barred by Buckman Company v. Plaintiffs’ Legal Committee, 531 U.S. 341 (2011), contending that the enforcement of those requirements is the exclusive prerogative of the federal government. And to the extent such public nuisance claims address reimbursement for prescription medications under state Medicaid programs, defendants may argue that these claims impermissibly conflict with federal law governing Medicaid programs. Moreover, even to the extent these claims were not found to be preempted, defendants may argue that the courts should defer to the FDA in resolving these matters under the doctrine of primary jurisdiction, which generally provides that issues committed to an administrative body should be addressed by it before being litigated.

In addition to preemption, defendants in these actions also may argue a failure of proximate causation due to the attenuated nature of the harm the plaintiffs allege. To the extent the suits are prosecuted in federal court, defendants may assert that the issue of causation may affect not only the merits of the action, but also the court’s jurisdiction, due to the plaintiffs’ lack of standing to bring the action in the first place. For example, courts generally have rejected public nuisance claims against producers of fatty foods for lack of standing on the ground that plaintiffs could not trace any health harm to those specific products, much less show that isolated uses of those products had caused harmful effects. Simpson v. Cal. Pizza Kitchen, Inc., 989 F. Supp. 2d 1015, 1022, 1025 (S.D. Cal. 2013). With similar reasoning, some judges have stated that global warming nuisance claims fail because the alleged harmful effects cannot be fairly attributed to particular defendants. Kivalina v. ExxonMobil Corp., 696 F.3d 849, 868 (9th Cir. 2012) (Pro, J. concurring). Pharmaceutical defendants may similarly contend that the harm alleged in the opioid nuisance litigation—increased healthcare costs to taxpayers from addiction—is not traceable to the defendants given the large number of factors that can cause or contribute to addiction. Defendants may also argue that an alleged link between the alleged conduct and injury was broken by other factors, including the criminal actions of third parties.

Finally, defendants may assert that public nuisance claims against pharmaceutical defendants fail because they do not allege interference with a “public right,” which is one of “those indivisible resources shared by the public at large, such as air, water, or public rights of way.” State v. Lead Indus. Ass’n, Inc., 951 A.2d 428, 453 (R.I. 2008); City of Chicago v. Am. Cyanamid Co., 823 N.E.2d 126, 131 (Ill. App. Ct. 2005). Courts generally have rejected nuisance claims against the firearms industry due to the lack of a public right to be “free from unreasonable jeopardy to health, welfare and safety . . . caused by the presence of illegal weapons.” City of Chicago v. Beretta U.S.A. Corp., 821 N.E.2d 1099, 1114 (Ill. 2004); accord City of Philadelphia v. Beretta U.S.A., Corp., 126 F. Supp. 2d 882, 909, 911 (E.D. Pa. 2000), aff’d, 277 F.3d 415 (3d Cir. 2002). Pharmaceutical defendants may assert that the new nuisance actions are on similar footing, because they allege harm due to illegal, not legal, use of the products. Defendants should continue to monitor the assertion of public nuisance claims against the pharmaceutical industry and be prepared to develop these and other potential defenses to such claims.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Quinn Emanuel Urquhart & Sullivan, LLP | Attorney Advertising

Written by:

Quinn Emanuel Urquhart & Sullivan, LLP

Quinn Emanuel Urquhart & Sullivan, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.